SCHEMBL2870299

SCHEMBL2870299

CCC(=O)c1ccc(Cl)cc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
KDM4E B2RXH2 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
FLT1 P17948 1/20 0.46
FLT4 P35916 1/20 0.46
KDR P35968 1/20 0.46
HSP90AB1 P08238 1/20 0.46
MAPK1 P28482 1/20 0.46
HIF1A Q16665 1/20 0.46
KCNH2 Q12809 1/20 0.43
POLB P06746 2/20 0.42
THRB P10828 1/20 0.42
RECQL P46063 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 3/20 0.42
LMNA P02545 2/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29444021 1.00 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL6744997 0.86 TSHR (0.51) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL27598378 0.85 F2R (0.48) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL30702134 0.83 GSK3B (0.52) ALDH1A1SMN1; SMN2KDM4EFLT1FLT4
SCHEMBL7779200 0.83 GSK3B (0.52) ALDH1A1SMN1; SMN2KDM4EFLT1FLT4
SCHEMBL27604216 0.82 MMP1 (0.43) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL20364210 0.81 FLT1 (0.46) ALDH1A1SMN1; SMN2KDM4EFLT1FLT4
SCHEMBL29712843 0.81 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL6174178 0.81 HSP90AB1 (0.48) ALDH1A1SMN1; SMN2KMT2AFLT1FLT4
SCHEMBL1144066 0.81 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117164523-A Oxo-pyridine compound and preparation method and application thereof 成都施贝康生物医药科技有限公司 2023-12-05 CN disclosed
CN-116768897-A Tetraazatricyclic compound and preparation method and application thereof 深圳信立泰药业股份有限公司 2023-09-19 CN disclosed
CN-113929618-B Oxo-pyridine amide derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2023-08-11 CN disclosed
CN-116120240-A FXIa inhibitor compound, preparation method and medical application thereof 深圳信立泰药业股份有限公司 2023-05-16 CN disclosed
CN-113912586-B Oxopyridine amide derivatives, preparation method thereof and application thereof in medicines 江苏恒瑞医药股份有限公司 2023-04-07 CN disclosed
CN-114206854-B FXIa inhibitor and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2023-02-24 CN disclosed
US-20230027295-A1 FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2023-01-26 US disclosed
US-20230027295-A1 FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2023-01-26 US disclosed
CN-111875559-B Thiazole hydrazide derivatives and application thereof as agricultural bactericide 南京农业大学 2022-11-22 CN disclosed
EP-4036087-A1 FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Shenzhen Salubris Pharmaceuticals Co. Ltd (CN) 2022-08-03 EP disclosed
CN-1980664-A CRTH2 receptor ligands for therapeutic use 7TM PHARMA AS (DK) 2007-06-13 CN disclosed
CN-1662513-A 2-thioxothiazole derivative, method for preparing the same, and pharmaceutical composition containing the same CJ CORP (KR) 2005-08-31 CN disclosed
CN-1210275-C Respiratory syncytial virus replication inhibitors JANSSEN PHARMACEUTICA NV (BE) 2005-07-13 CN disclosed
CN-1358181-A Respiratory syncytial virus replication inhibitors JANSSEN PHARMACEUTICA NV (BE) 2002-07-10 CN disclosed
CN-1068000-C Apolipoprotein-B synthesis inhibitors JANSSEN PHARMACEUTICA NV (BE) 2001-07-04 CN disclosed
CN-1201453-A 4- (cycloalkyl) -piperidine and 4- (cycloalkylalkyl) piperidine derivatives, their preparation and their use in medicine SYNTHELABO CO (FR) 1998-12-09 CN disclosed
CN-1162596-A Antiarrhythmic Agents AMERICAN CYANAMID CO (US) 1997-10-22 CN disclosed
CN-1161695-A Apolioprotein-B synthesis inhibitors JANSSEN PHARMACEUTICA NV (BE) 1997-10-08 CN disclosed
CN-1071420-A 4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl] phenyl]-5-methyl-3H-1,2,4-triazole-3-ketone derivatives JANSSEN PHARMACEUTICA NV (BE) 1993-04-28 CN disclosed
EP-0092239-A2 Oxazole derivatives, production and use thereof Takeda Chemical Industries, Ltd. (JP) 1983-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027295-A1 FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF F11, TFPI, F7 ALDH1A1 3516/4885SMN1; SMN2 4363/4885KDM4E 1793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.